

CSD/NSE&BSE/RPT/2022-23
November 21, 2022

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

.....

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions and balances for the half-year ended 30th September, 2022.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**

K. Hanumantha Rao
Company Secretary

Encl: as above

Suven Pharmaceuticals Limited

Registered Office: # 8-2-334 | SDE Serene Chambers | 3rd Floor | Road No.5

Avenue 7 | Banjara Hills | Hyderabad - 500034 | Telangana | India | CIN: L24299TG2018PLC128171

Tel: 91 40 2354 9414 /1142 /3311 | Fax: 91 40 2354 1152 | Email: info@suvenpharm.com | www.suvenpharm.com

Sl. No	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
											In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary			Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)	
1	Suven Pharmaceuticals Ltd.		Suven Life Sciences Limited		Company under the Control of Key Managerial Personnel	Lease Rental Income	114.06 p.a.	56.42										
2	Suven Pharmaceuticals Ltd.		Suven Life Sciences Limited		Company under the Control of Key Managerial Personnel	Availing Service charges	10000.00 per Financial Year	717.23										
3	Suven Pharmaceuticals Ltd.		Casper Pharma Private Limited		Wholly Owned Subsidiary	Lease Rental Income	Not applicable	2.02										
4	Suven Pharmaceuticals Ltd.		Mr. Venkateswarlu Jasti		Key Managerial Personnel	Short term employee benefits	525.33	525.33										
5	Suven Pharmaceuticals Ltd.		Mrs Kalyani Jasti		Relative of Key Managerial Personnel	Short term employee benefits	180.22	180.22										
6	Suven Pharmaceuticals Ltd.		Mr. D. G. Prasad		Key management personnel	Sitting fee	Not applicable	3.20										
7	Suven Pharmaceuticals Ltd.		Mrs. Deepanwita Chattopadhyay		Key Managerial Personnel	Sitting fee	Not applicable	2.20										
8	Suven Pharmaceuticals Ltd.		Mr. J. V. Ramudu		Key Managerial Personnel	Sitting fee	Not applicable	2.40										
9	Suven Pharmaceuticals Ltd.		Mr. V. Sambasiva Rao		Key Managerial Personnel	Sitting fee	Not applicable	3.20										

- Notes: 1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months' period shall apply accordingly
5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
6. In case of a multi-year related party transaction:
- a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
- b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
7. "Cost" refers to the cost of borrowed funds for the listed entity.
8. PAN will not be displayed on the website of the Stock Exchange(s).
9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.